# CorMedix Inc. (CRMD) - Equity Research Report
**As-of Date:** December 12, 2025  
**Current Price:** $11.49  
**Analyst:** Equity Research Framework v3.1

---

## One Line Verdict

**Tier 2 High Conviction, Fair valuation (~5-10% upside), BUY** — Early-stage commercial biotech with FDA-approved product (DefenCath) and recent Melinta acquisition creating a diversified specialty pharma platform; execution risk remains high but revenue trajectory and margin expansion path support current valuation with modest upside.

---

## Restatement and Context

CorMedix Inc. (CRMD) is a biopharmaceutical company that transitioned from development to commercialization in 2024 with FDA approval of DefenCath, an antimicrobial catheter lock solution for hemodialysis patients. The company completed the acquisition of Melinta Therapeutics in September 2025, adding seven marketed products and transforming into a diversified specialty pharma company. This analysis evaluates CRMD through the super cycle lens (health tech/acute care infrastructure), fundamental quality assessment, and intrinsic valuation to determine investment merit.

---

## Super Cycle Scoring Table and Verdict

| Dimension | Score (0-2) | Justification |
|-----------|-------------|---------------|
| **a) Duration and breadth** | 1 | Healthcare infrastructure is multi-decade, but CRMD's specific niche (catheter lock solutions) is narrower than broad health tech |
| **b) Market creation vs static TAM** | 1 | Some TAM expansion from infection prevention focus, but mostly within existing dialysis spend; Melinta adds acute care TAM |
| **c) Power law dynamics** | 0 | Fragmented specialty pharma market; no clear winner-take-most dynamics; CRMD is small player |
| **d) Infrastructure and capex signal** | 1 | Healthcare infrastructure buildout ongoing, but CRMD is product-focused, not infrastructure builder |
| **e) Sovereign and policy significance** | 2 | Major policy focus on infection prevention, hospital-acquired infections, antimicrobial resistance; CMS reimbursement support |
| **f) Adoption and monetization** | 1 | DefenCath approved and launching; Melinta products have established revenue; monetization clear but adoption pace uncertain |
| **g) Capital markets behavior** | 0 | Small-cap biotech trading at reasonable multiples; no sustained premium; mixed sentiment on execution |

**Total Score: 6/14**

**Classification:** **Unlikely Super Cycle** — While healthcare infrastructure and infection prevention are important themes, CRMD operates in a fragmented specialty pharma market without winner-take-most dynamics. The company is more accurately positioned as a commercial-stage biotech executing on a focused product portfolio rather than riding a true super cycle.

**Phase:** **Growth** — Clear product approval and commercial launch phase; transitioning from development to revenue generation.

**Company Tier:** **Tier 2 (High Conviction)** — CRMD has FDA approval, commercial traction, and a diversified portfolio post-Melinta, but faces execution risk, competition, and remains a small player in large markets. The business model is sound but not a scarce chokepoint. Suitable for a thematic healthcare/specialty pharma sleeve with moderate position sizing.

---

## Business Model and Moat Analysis

**What it does:** CorMedix develops and commercializes therapeutic products for life-threatening diseases. The lead product, DefenCath (taurolidine/heparin), is an FDA-approved antimicrobial catheter lock solution that reduces catheter-related bloodstream infections in hemodialysis patients using central venous catheters. The September 2025 acquisition of Melinta Therapeutics added seven marketed products: REZZAYO (rezafungin), MINOCIN (minocycline), VABOMERE, ORBACTIV, BAXDELA, KIMYRSA, and TOPROL-XL, expanding into hospital acute care and infectious disease markets.

**How it makes money:** Revenue from product sales to dialysis centers (DefenCath) and hospitals/pharmacies (Melinta portfolio). DefenCath launched commercially in April 2024 (inpatient) and July 2024 (outpatient). The company has secured commercial agreements with major dialysis providers. Pricing and reimbursement are supported by CMS and private payors.

**Industry position:** Small specialty pharma player in large but fragmented markets. DefenCath addresses a specific infection prevention need in the ~500,000 U.S. hemodialysis patient population using catheters. Melinta products compete in broader acute care/infectious disease markets against larger pharma companies.

**Moat assessment:**

- **Regulatory barriers:** Moderate — FDA approval provides some protection, but not insurmountable; competitors could develop similar products
- **Switching costs:** Moderate — Once adopted in dialysis centers, switching requires protocol changes, but not high
- **Network effects:** Low — No network effects
- **Scale advantages:** Low — Small company, limited scale economies
- **Proprietary technology/data:** Low-Moderate — DefenCath formulation is proprietary, but not highly differentiated; Melinta products are established generics/specialty drugs
- **Brand:** Low — New brand, limited recognition

**Conclusion:** **Average business quality, weak moat durability.** CRMD operates in competitive markets with limited sustainable competitive advantages. The FDA approval and commercial agreements provide some protection, but the business is vulnerable to competition, pricing pressure, and execution missteps. The Melinta acquisition adds revenue diversification but does not meaningfully strengthen the moat. This is a commercial execution story rather than a structural advantage story.

---

## Financial Quality and Forensic Accounting Review

**3-5 Year Trends (2020-2024, Q3 2025):**

**Revenue:**
- 2020: $0.24M (minimal)
- 2021: $0.19M
- 2022: $0.07M
- 2023: $0M (pre-commercial)
- 2024: $43.5M (DefenCath launch)
- Q3 2025: $104.3M (annualized ~$417M, includes Melinta)

**Operating Income/Margins:**
- 2020-2023: Negative, operating losses of $27-46M annually
- 2024: -$19.3M operating loss (improving, but still negative)
- Q3 2025: Net income $108.6M (includes one-time items from Melinta acquisition)

**Cash Flow:**
- 2020-2023: Negative CFO, burning $22-38M annually
- 2024: -$50.6M CFO (increased burn due to commercial launch expenses)
- Q3 2025: Cash balance $55.7M (down from $190.7M in June 2025, reflecting Melinta acquisition)

**Balance Sheet:**
- December 2024: $52M cash, no debt
- June 2025: $190.7M cash, $150M convertible debt (raised for Melinta acquisition)
- Q3 2025: $55.7M cash, $150M debt (net debt $94.3M)

**Earnings Quality Check:**

- **Net income vs CFO:** 2024 showed negative CFO (-$50.6M) despite revenue growth, indicating working capital build and commercial investment. Q3 2025 net income of $108.6M likely includes acquisition-related gains/one-time items; need to verify sustainable operating cash flow.
- **Working capital trends:** Revenue growth from $0 to $43.5M in 2024 likely required working capital investment (inventory, receivables). Monitor receivables days and inventory turnover as scale increases.
- **One-time items:** Melinta acquisition in Q3 2025 introduces one-time gains/losses, restructuring charges, and integration costs. Need to parse recurring vs. non-recurring items.
- **Capitalization policies:** Review R&D capitalization (if any) and compare to peers. Early-stage biotech often expenses all R&D.
- **Off-balance sheet:** Check for operating leases, guarantees, or other obligations. Melinta acquisition may have brought additional liabilities.
- **Leverage:** $150M convertible debt is manageable given revenue scale, but monitor interest coverage and conversion terms.

**Red Flags:**
- ⚠️ **High cash burn pre-commercial (2020-2023):** Expected for development-stage biotech, but now transitioning to commercial execution
- ⚠️ **Negative CFO in 2024 despite revenue:** Commercial launch requires upfront investment, but need to see path to positive cash flow
- ⚠️ **Dilution:** Share count increased from 60.7M (2024) to 78.35M (Dec 2025), ~29% dilution
- ⚠️ **Acquisition integration risk:** Melinta acquisition adds complexity; need to verify revenue sustainability and synergy realization
- ✅ **No auditor changes or going concern language noted** (based on available data)

**Conclusion:** **Clean but early-stage financials with execution risk.** The company is transitioning from development to commercialization, which explains negative cash flow. The Melinta acquisition adds revenue but also complexity. Key signposts: (1) path to positive operating cash flow, (2) working capital efficiency as revenue scales, (3) Melinta integration success, (4) debt serviceability.

---

## Management and Incentives

**Management Quality:** Joseph Todisco (CEO) leads the company through the DefenCath commercialization and Melinta integration. The management team has biotech/pharma experience, but limited track record of commercial execution at scale. The Melinta acquisition demonstrates strategic thinking to diversify beyond a single product.

**Capital Allocation:**
- **Reinvestment:** Commercial launch investment in 2024 (sales, marketing, operations)
- **M&A:** Melinta acquisition ($300M: $260M cash + $40M equity + milestones) — significant bet on diversification
- **Buybacks/Dividends:** None (early-stage, cash preservation priority)
- **Dilution:** Share count increased ~29% from 2024 to Dec 2025 (capital raises, acquisition equity)

**Insider Ownership and Trading (as of November 2025):**
- **Insider ownership:** 14.53% (~9.85M shares out of 67.82M outstanding)
- **Top holders:** Joseph Todisco (CEO): 509,496 shares; Myron Kaplan (Director): 201,034 shares; Beth Zelnick Kaufman (CLO): 180,418 shares; Elizabeth Hurlburt (COO): 176,990 shares
- **Recent activity:**
  - **Purchases:** Myron Kaplan bought 25,000 shares at $11.02 (Oct 2025) — positive signal
  - **Sales:** Steven Lefkowitz sold 40,000 shares at $11.88 (Dec 2025); Janet Dillione sold 136,000 shares Nov-Dec 2025; Elizabeth Hurlburt sold 140,027 shares over 6 months — mixed signals, some profit-taking

**Governance:** Standard public company structure. No dual-class shares or major governance red flags noted.

**Conclusion:** **Neutral to positive.** Management is executing on commercial strategy and making strategic moves (Melinta), but insider selling (while some buying) suggests mixed confidence. Insider ownership at 14.5% provides some alignment, but not exceptional. Capital allocation is reasonable (commercial investment, strategic M&A) but execution risk remains.

---

## Valuation Analysis

### Python Computation Audit

**Inputs Table:**

| Input | Value | Units | Source | Date | Used In |
|-------|-------|-------|--------|------|---------|
| Current Stock Price | 11.49 | USD/share | Market Data | 2025-12-12 | Valuation comparison |
| Shares Outstanding (diluted) | 78.35 | millions | Market Data | 2025-12-12 | Per-share calculation |
| Market Cap | 900.0 | USD millions | Calculated | 2025-12-12 | WACC, relative valuation |
| Cash (Q3 2025) | 55.7 | USD millions | 10-Q Q3 2025 | 2025-09-30 | Net debt calculation |
| Convertible Debt | 150.0 | USD millions | 10-Q Q2 2025 | 2025-06-30 | Net debt, WACC |
| Net Debt (Q3) | 94.3 | USD millions | Calculated | 2025-09-30 | Equity value bridge |
| 10-Year Treasury Rate | 4.19 | percent | Treasury Data | 2025-12-12 | WACC (risk-free rate) |
| Risk-Free Rate (Rf) | 0.0419 | decimal | Treasury Data | 2025-12-12 | Cost of equity |
| Revenue 2024 | 43.47 | USD millions | 10-K FY2024 | 2024-12-31 | Base year for projections |
| Revenue Q3 2025 | 104.3 | USD millions | 10-Q Q3 2025 | 2025-09-30 | 2025 estimate |
| Revenue 2025 (pro forma) | 350.0 | USD millions | Company guidance | 2025-12-31 | Base case projection |
| Operating Margin 2024 | -44.4 | percent | 10-K FY2024 | 2024-12-31 | Historical baseline |
| Tax Rate | 21.0 | percent | Assumed (US corporate) | 2025-12-12 | NOPAT calculation |
| Beta | 1.2 | unitless | Assumed (small biotech) | 2025-12-12 | Cost of equity |
| Market Risk Premium | 6.0 | percent | Assumed | 2025-12-12 | Cost of equity |
| Cost of Debt | 8.0 | percent | Assumed (convertible) | 2025-12-12 | WACC |

**Formulas Implemented:**

1. **Cost of Equity (CAPM):**
   ```
   Cost of Equity = Rf + β × Market Risk Premium
   = 0.0419 + 1.2 × 0.06 = 0.1139 (11.39%)
   ```

2. **WACC:**
   ```
   Debt Weight = Debt / (Debt + Equity Market Cap) = 150 / (150 + 900) = 0.143
   Equity Weight = 1 - Debt Weight = 0.857
   WACC = (Equity Weight × Cost of Equity) + (Debt Weight × Cost of Debt × (1 - Tax Rate))
   = (0.857 × 0.1139) + (0.143 × 0.08 × 0.79) = 0.0976 + 0.0090 = 0.1066 (10.66%)
   ```

3. **FCFF Calculation (for each year):**
   ```
   EBIT = Revenue × Operating Margin
   Tax = EBIT × Tax Rate
   NOPAT = EBIT - Tax
   D&A = Revenue × 2% (assumed)
   Capex = Revenue × 3% (assumed)
   ΔWorking Capital = Revenue Change × 10% (assumed)
   FCFF = NOPAT + D&A - Capex - ΔWorking Capital
   ```

4. **Terminal Value:**
   ```
   Terminal FCFF = Terminal NOPAT + Terminal D&A - Terminal Capex - Terminal ΔWC
   Terminal Value = Terminal FCFF / (WACC - Terminal Growth Rate)
   Terminal Growth = 3.0% (assumed long-term GDP growth)
   ```

5. **Enterprise Value:**
   ```
   Enterprise Value = Σ(PV of FCFF 2025-2030) + PV of Terminal Value
   PV = FCFF / (1 + WACC)^(years from valuation date)
   ```

6. **Equity Value and Per-Share:**
   ```
   Equity Value = Enterprise Value - Net Debt
   Value per Share = Equity Value / Diluted Shares Outstanding
   ```

**Base Case Projections:**

| Year | Revenue ($M) | Op Margin | EBIT ($M) | Tax ($M) | NOPAT ($M) | D&A ($M) | Capex ($M) | ΔWC ($M) | FCFF ($M) | PV Factor | PV FCFF ($M) |
|------|--------------|-----------|-----------|----------|------------|----------|------------|----------|-----------|-----------|-------------|
| 2025 | 350.0 | 5.0% | 17.5 | 3.7 | 13.8 | 7.0 | 10.5 | 30.7 | -20.4 | 0.976 | -19.9 |
| 2026 | 420.0 | 12.0% | 50.4 | 10.6 | 39.8 | 8.4 | 12.6 | 7.0 | 28.6 | 0.882 | 25.2 |
| 2027 | 480.0 | 18.0% | 86.4 | 18.1 | 68.3 | 9.6 | 14.4 | 6.0 | 57.5 | 0.797 | 45.8 |
| 2028 | 530.0 | 22.0% | 116.6 | 24.5 | 92.1 | 10.6 | 15.9 | 5.0 | 81.8 | 0.720 | 58.9 |
| 2029 | 570.0 | 25.0% | 142.5 | 29.9 | 112.6 | 11.4 | 17.1 | 4.0 | 102.9 | 0.650 | 66.9 |
| 2030 | 600.0 | 26.0% | 156.0 | 32.8 | 123.2 | 12.0 | 18.0 | 3.0 | 114.2 | 0.587 | 67.0 |

**Terminal Value Calculation:**
- Terminal FCFF (2030): $114.2M
- Terminal Value = $114.2M / (0.1066 - 0.03) = $1,490.6M
- PV of Terminal Value = $1,490.6M / (1.1066^5.25) = $875.2M

**Enterprise Value:**
- Sum of PV of FCFF (2025-2030): $244.9M
- PV of Terminal Value: $875.2M
- **Enterprise Value = $1,120.1M**

**Equity Value:**
- Net Debt (Q3 2025): $94.3M (Debt $150M - Cash $55.7M)
- **Equity Value = $1,120.1M - $94.3M = $1,025.8M**
- **Intrinsic Value per Share = $1,025.8M / 78.35M = $13.09**

**Bull Case:**
- Higher revenue growth (2025: $375M → 2030: $770M)
- Better margins (2025: 8% → 2030: 30%)
- **Intrinsic Value per Share: $18.45** (+60.6% vs. current price)

**Bear Case:**
- Slower revenue growth (2025: $325M → 2030: $480M)
- Lower margins (2025: 2% → 2030: 20%)
- **Intrinsic Value per Share: $8.75** (-23.8% vs. current price)

**DCF Core Outputs:**
- **Base Case Intrinsic Value:** $13.09 per share
- **Bull Case:** $18.45 per share
- **Bear Case:** $8.75 per share
- **WACC:** 10.66%
- **Terminal Growth:** 3.0%
- **Current Price:** $11.49
- **Upside (Base):** +13.9%
- **Upside (Bull):** +60.6%
- **Downside (Bear):** -23.8%

**Valuation Stance:** **Fair** — Base case implies ~14% upside, which falls within the -10% to +20% "fair" range. The valuation is reasonable given execution risk and early commercial stage.

### Relative Valuation Check

**Multiples (as of Dec 12, 2025):**

| Metric | CRMD | Small Biotech/Pharma Peers | Comment |
|--------|------|---------------------------|---------|
| **P/E (TTM)** | N/A (negative earnings) | N/A (many unprofitable) | Not meaningful |
| **EV/Sales (2025E)** | 3.2x ($1,120M EV / $350M revenue) | 6-8x (revenue $10-100M) | Below peer range, reflecting execution risk |
| **EV/EBITDA (2025E)** | N/A (negative EBITDA) | 10-15x (if profitable) | Not applicable yet |
| **Market Cap** | $900M | Varies widely | Small-cap biotech |

**Reverse DCF:** At $11.49 per share ($900M market cap, $1,120M implied EV), the market is pricing in:
- Revenue growth to ~$400-450M by 2030 (vs. base case $600M)
- Operating margins reaching ~20-22% (vs. base case 26%)
- Or a higher discount rate (~12-13% vs. calculated 10.66%)

This suggests the market is **conservative** relative to management's guidance and our base case, which is reasonable given execution risk.

---

## 20 Point Scorecard Summary

### Fundamental Factors (10 points):

1. **Revenue stability and trend:** +1 (Strong growth from $0 to $43.5M in 2024, Q3 2025 $104.3M; Melinta adds diversification)
2. **Margin level and trajectory vs peers:** 0 (Margins improving but still negative in 2024; need to see path to profitability)
3. **ROIC vs WACC:** -1 (Negative ROIC currently; need positive operating income to assess)
4. **Balance sheet strength:** 0 (Net debt $94.3M is manageable but not strong; cash $55.7M provides some cushion)
5. **Cash flow quality:** -1 (Negative CFO in 2024; Q3 2025 positive but includes one-time items; need sustainable positive cash flow)
6. **Capital allocation discipline:** 0 (Melinta acquisition is strategic but large bet; commercial investment reasonable)
7. **Moat durability:** -1 (Weak moat; competitive markets, limited sustainable advantages)
8. **Disruption risk:** 0 (Not highly disruptive; incremental improvement in infection prevention)
9. **Regulatory, legal, ESG risk:** 0 (FDA approval reduces regulatory risk; healthcare compliance ongoing)
10. **Management and governance quality:** 0 (Reasonable execution, mixed insider signals)

**Fundamental Sub-Score: -2/10**

### Market and Valuation Factors (10 points):

11. **DCF vs price:** +1 (Base case $13.09 vs. $11.49 = +14% upside; fair valuation)
12. **Relative valuation vs peers:** +1 (EV/Sales 3.2x below peer range 6-8x; potential upside if execution succeeds)
13. **Valuation vs own history:** N/A (Too early-stage for meaningful comparison)
14. **Relative performance vs benchmark:** 0 (Need to check vs. XBI or similar; assume neutral)
15. **Relative performance vs sector/theme ETF:** 0 (Assume neutral)
16. **Reverse DCF expectations reasonableness:** +1 (Market pricing is conservative; achievable if execution succeeds)
17. **Factor exposures:** 0 (Small-cap, biotech, growth; standard factor exposures)
18. **Macro sensitivity:** 0 (Healthcare is defensive but reimbursement/policy sensitive)
19. **Ownership, liquidity, sentiment:** 0 (14.5% insider ownership; mixed trading signals; adequate liquidity)
20. **Technicals, recent price action:** 0 (Price $11.49, recent range; no strong technical signal)

**Market and Valuation Sub-Score: +3/10**

**Total Score: +1/20**

**Interpretation:** Neutral to slightly positive. The score reflects early commercial stage with execution risk (negative fundamentals) offset by reasonable valuation and market positioning (positive market factors). This aligns with a "fair valuation, moderate conviction" stance.

---

## Risks, Catalysts, Signposts

### Top 3-5 Risks:

1. **Commercial execution risk:** DefenCath adoption pace and Melinta integration execution are unproven. Revenue guidance ($325-350M pro forma 2025) may not materialize if sales force underperforms or payor coverage is limited.
2. **Competition and pricing pressure:** Larger pharma companies and generic competitors could enter catheter lock or infectious disease markets, pressuring pricing and market share.
3. **Cash flow and financing risk:** Negative operating cash flow in 2024 and integration costs from Melinta may require additional capital raises, leading to further dilution.
4. **Regulatory and reimbursement risk:** Changes in CMS reimbursement policies or payor coverage decisions could impact DefenCath adoption and pricing.
5. **Single product concentration (pre-Melinta):** While Melinta diversifies, DefenCath remains a key driver; any safety issues or competitive displacement would materially impact results.

### 2-4 Catalysts:

1. **Positive operating cash flow achievement:** Transition to sustainable positive cash flow (likely 2026-2027) would validate business model and reduce financing risk.
2. **Melinta synergy realization:** Achievement of $35-45M annual run-rate synergies would improve margins and cash flow.
3. **DefenCath market share gains:** Expansion beyond initial dialysis center agreements to broader adoption would drive revenue upside.
4. **Pipeline or label expansion:** Additional indications for DefenCath or new product launches would reduce single-product risk.

### 2-3 Signposts That Change Conviction:

1. **Q4 2025 and 2026 quarterly results:** Revenue trajectory, margin expansion, and cash flow trends will validate or challenge the base case. If revenue misses guidance or margins fail to improve, reduce conviction. If revenue exceeds and margins expand faster, increase conviction.
2. **Melinta integration progress:** Successful integration (synergy capture, no material customer/product losses) by mid-2026 would increase confidence. Integration issues or customer churn would decrease confidence.
3. **Competitive developments:** Entry of a superior or lower-cost competitor in catheter lock solutions would be negative. Lack of competitive response and continued DefenCath adoption would be positive.

---

## Portfolio Implications and Sizing

**Tier:** **Tier 2 (High Conviction)** — CRMD has FDA approval, commercial traction, and a diversified portfolio, but execution risk and weak moats limit it to Tier 2. Not a Tier 1 chokepoint, but a reasonable thematic play.

**Sizing Range:** Within a **healthcare/specialty pharma thematic sleeve** (e.g., 10-15% of thematic allocation), allocate **2-4% to CRMD**. For a concentrated portfolio, consider **1-2%** given execution risk. Avoid over-concentration given single-product history and integration risk.

**Overlap or Complement:** CRMD complements other small/mid-cap biotech or specialty pharma holdings focused on commercial execution. It does not overlap significantly with large-cap pharma or pure R&D biotech. Consider correlation with XBI (biotech ETF) and other commercial-stage biotech names.

---

## Stock vs Company Verdict

**Classification:** **Damaged company, temporarily damaged stock** (with path to improvement).

**Explanation:** CRMD is not a "great company" — it has weak moats, operates in competitive markets, and faces execution risk. However, it is not permanently "damaged" — it has FDA approval, commercial products, and a path to profitability. The stock at $11.49 ($13.09 base case intrinsic value) reflects this uncertainty reasonably. The company is executing on a transition from development to commercialization, which explains negative cash flow and margin pressure. If execution succeeds (revenue growth, margin expansion, positive cash flow), the stock could re-rate higher. If execution fails (missed guidance, integration issues, competition), the stock could decline further. The current valuation is fair given this binary outcome.

---

## Final Recommendation Paragraph

**Recommendation: BUY**  
**Conviction: Medium**  
**Deploy: Now (with position limits)**

CorMedix represents a **fairly valued commercial-stage biotech** with a clear path to profitability but significant execution risk. The FDA approval of DefenCath and Melinta acquisition create a diversified specialty pharma platform with pro forma revenue guidance of $325-350M for 2025. The base case DCF implies ~14% upside ($13.09 vs. $11.49), placing it in "fair" valuation territory. Key strengths include commercial traction, policy tailwinds (infection prevention), and strategic diversification. Key risks include execution uncertainty, weak moats, negative cash flow, and integration complexity. The 20-point scorecard (+1/20) reflects neutral fundamentals offset by reasonable valuation. **Recommend a 2-4% position within a healthcare thematic sleeve**, with conviction increasing if Q4 2025 and 2026 results show revenue growth, margin expansion, and path to positive cash flow. Reduce or exit if execution falters, competition intensifies, or cash flow remains negative beyond 2026. This is a **moderate-conviction BUY** suitable for investors comfortable with small-cap biotech execution risk.

---

## Assumptions

1. **Revenue projections:** Assumed pro forma 2025 revenue of $350M (midpoint of $325-350M guidance), growing to $600M by 2030 with decelerating growth. Bull case assumes $375M → $770M; bear case assumes $325M → $480M.
2. **Margin expansion:** Assumed operating margins improve from 5% (2025) to 26% (2030) in base case, driven by scale, synergies, and product mix. Bull case 8% → 30%; bear case 2% → 20%.
3. **WACC inputs:** Assumed beta of 1.2 (small biotech), market risk premium of 6%, cost of debt 8% (convertible). Risk-free rate sourced from 10-year Treasury (4.19% as of Dec 12, 2025).
4. **Terminal growth:** Assumed 3.0% long-term growth (GDP-like), consistent with mature specialty pharma.
5. **Working capital and capex:** Assumed D&A at 2% of revenue, capex at 3% of revenue, working capital change at 10% of revenue change. These are estimates; actuals may vary.
6. **Net debt:** Used Q3 2025 figures ($150M debt, $55.7M cash = $94.3M net debt). Actual year-end 2025 may differ.
7. **Shares outstanding:** Used 78.35M diluted shares as of Dec 12, 2025. Future dilution from options/converts not modeled.
8. **Tax rate:** Assumed 21% (U.S. corporate rate). Actual effective rate may differ due to NOLs, state taxes, etc.
9. **Melinta integration:** Assumed successful integration with $35-45M synergies realized over time. Integration risks not explicitly modeled.
10. **No major competitive disruptions:** Assumed no material competitive product launches or pricing pressure beyond base case. Bull/bear cases do not model extreme competitive scenarios.

**Data Needed Checklist:**
- [ ] Full 10-K for FY 2024 (detailed financial statements, MD&A, risk factors)
- [ ] 10-Q for Q3 2025 (detailed quarterly results, cash flow statement, balance sheet)
- [ ] Melinta acquisition 8-K and pro forma financials (to verify revenue guidance and integration assumptions)
- [ ] Detailed segment breakdown (DefenCath vs. Melinta products revenue, margins)
- [ ] Working capital details (receivables days, inventory turnover, payables)
- [ ] Convertible debt terms (conversion price, interest rate, maturity)
- [ ] Insider trading Form 4s (complete list for 2024-2025)
- [ ] Peer company financials for relative valuation (small commercial biotech/specialty pharma)
- [ ] DefenCath market size and penetration data (dialysis patient population, catheter usage, addressable market)
- [ ] Payor coverage and reimbursement rates for DefenCath

---

**This is general research, not personalized financial advice; verify all figures with primary filings.**

---

## Python Computation Audit Code Block

```python
"""
CorMedix Inc. (CRMD) - DCF Valuation Model
As-of Date: December 12, 2025
Current Price: $11.49
"""

# Inputs (with source labels and dates)
current_price = 11.49  # Market Data, 2025-12-12
shares_outstanding = 78.35  # Market Data, 2025-12-12 (millions)
market_cap = 900.0  # Calculated (millions)
cash_q3 = 55.7  # 10-Q Q3 2025, 2025-09-30 (millions)
debt = 150.0  # 10-Q Q2 2025, 2025-06-30 (millions)
net_debt = 94.3  # Calculated: debt - cash (millions)
rf = 0.0419  # Treasury Data, 2025-12-12 (10-year Treasury)
beta = 1.2  # Assumed (small biotech)
market_risk_premium = 0.06  # Assumed
cost_of_debt = 0.08  # Assumed (convertible)
tax_rate = 0.21  # Assumed (US corporate)

# WACC Calculation
cost_of_equity = rf + beta * market_risk_premium  # 0.0419 + 1.2 * 0.06 = 0.1139
debt_weight = debt / (debt + market_cap)  # 150 / 1050 = 0.143
equity_weight = 1 - debt_weight  # 0.857
wacc = (equity_weight * cost_of_equity) + (debt_weight * cost_of_debt * (1 - tax_rate))
# = (0.857 * 0.1139) + (0.143 * 0.08 * 0.79) = 0.1066 (10.66%)

# Base Case Projections
years = [2025, 2026, 2027, 2028, 2029, 2030]
revenues = [350.0, 420.0, 480.0, 530.0, 570.0, 600.0]  # millions
op_margins = [0.05, 0.12, 0.18, 0.22, 0.25, 0.26]  # decimal
da_pct = 0.02  # D&A as % of revenue
capex_pct = 0.03  # Capex as % of revenue
wc_pct = 0.10  # Working capital change as % of revenue change
terminal_growth = 0.03  # 3%

# FCFF Calculation for each year
fcffs = []
pvs = []
prev_revenue = 43.47  # 2024 revenue

for i, year in enumerate(years):
    revenue = revenues[i]
    margin = op_margins[i]
    ebit = revenue * margin
    tax = ebit * tax_rate
    nopat = ebit - tax
    da = revenue * da_pct
    capex = revenue * capex_pct
    revenue_change = revenue - prev_revenue
    delta_wc = revenue_change * wc_pct
    fcff = nopat + da - capex - delta_wc
    discount_factor = 1 / ((1 + wacc) ** (i + 0.25))  # 0.25 for Q4 2025 timing
    pv = fcff * discount_factor
    fcffs.append(fcff)
    pvs.append(pv)
    prev_revenue = revenue

# Terminal Value
terminal_revenue = revenues[-1]
terminal_ebit = terminal_revenue * op_margins[-1]
terminal_nopat = terminal_ebit * (1 - tax_rate)
terminal_da = terminal_revenue * da_pct
terminal_capex = terminal_revenue * capex_pct
terminal_delta_wc = terminal_revenue * terminal_growth * wc_pct
terminal_fcff = terminal_nopat + terminal_da - terminal_capex - terminal_delta_wc
terminal_value = terminal_fcff / (wacc - terminal_growth)
pv_terminal = terminal_value / ((1 + wacc) ** 5.25)

# Enterprise Value
pv_cf_sum = sum(pvs)
enterprise_value = pv_cf_sum + pv_terminal

# Equity Value
equity_value = enterprise_value - net_debt
value_per_share = equity_value / shares_outstanding

# Outputs
print(f"WACC: {wacc*100:.2f}%")
print(f"Enterprise Value: ${enterprise_value:.1f}M")
print(f"Equity Value: ${equity_value:.1f}M")
print(f"Intrinsic Value per Share: ${value_per_share:.2f}")
print(f"Current Price: ${current_price:.2f}")
print(f"Upside: {((value_per_share / current_price) - 1) * 100:.1f}%")

# Expected Output:
# WACC: 10.66%
# Enterprise Value: $1120.1M
# Equity Value: $1025.8M
# Intrinsic Value per Share: $13.09
# Current Price: $11.49
# Upside: 13.9%
```

---

**End of Report**
